Copyright 2012 - 2013 TJ Capital Management & TJInvestor.com  All Rights Reserved. 版權所有,翻印必究。
免責條款
本網站中的資訊均來自可靠渠道,但我們不保證其完整性與正確性。網站中的各種信息可能在未經告知的情況下已放生變化。任何時候本網站編輯人員、公司員工或本公司管理之基金都可能持有、賣空或曾經持有現已賣出網站
中列出的股票。股票過去的表現不代表未來的投資結果。本網站不是建議投資者買進或賣出所介紹的股票,網站中的信息和建議僅供投資者參考,投資者的投資決定取決於其對市場、個股及投資風險的認知程度。請投資者在投
資本網站所列出之股票前,應向其個人投資顧問咨詢。
Sources of the information obtained in this website are deemed to be reliable; however, we do not guarantee the sequence, timeliness, accuracy or completeness of the information.  All informations are subject to change without
notice.

Nothing on the site and no site information is a recommendation, advice or solicitation to buy, sell or hold securities or financial instruments. Anytime, we may have a long or short position in securities mentioned. Past performance
is not a guarantee of future results. Hypothetical, modeled or simulated performance results have inherent limitations, and do not represent actual trading.

The site and site information is for informational, educational and personal use only. You agree that the use of this website is at your own risk and do your own independent research in order to allow you to form your own opinion
regarding investments. You should consult with your brokers, financial and legal advisors concerning trading decisions and any relevant.
進場簡明報告樣本
買入 AbbVie Inc. (ABBV) 12/03/13
 
ABBV 是全球主要的制藥商,2013年初從Abbott(ABT)分出獨立上市。公司研發的藥品主要用於治療免
疫系統、神經系統疾病及腎病和血脂症等,旗艦產品Humira目前占銷售的50%。公司擁有大量在晚期試
驗或已向FDA申請上市許可的藥品。
 
行業
制藥業
主要同行
ABT, PFE, MRK, JNJ, NVS
買入價:
$49.38
原始停損價:
$47.92
 
 
TC2000 charts used courtesy of Worden Brothers, Inc.